1. Synthesis of new piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of Candida albicans multidrug transporters by a Buchwald–Hartwig cross-coupling reaction
- Author
-
Rajendra Prasad, Attilio Di Pietro, Shweta Nim, Stéphane Moreau, Elisabeth Thivet, Luisa Ronga, Marc Le Borgne, Solène Savrimoutou, Mathieu Marchivie, Jean Guillon, Régulations Naturelles et Artificielles (ARNA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux Ségalen [Bordeaux 2], Jawaharlal Nehru University (JNU), Institut de Chimie de la Matière Condensée de Bordeaux (ICMCB), Université de Bordeaux (UB)-Institut Polytechnique de Bordeaux-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut de biologie et chimie des protéines [Lyon] (IBCP), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS), Amity Institute of Integrative Sciences and Health, Amity University, Molécules bioactives et chimie médicinale (B2MC), Université de Lyon-Université de Lyon, and Le Borgne, Marc
- Subjects
0303 health sciences ,[SDV.SP.MED] Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,biology ,030306 microbiology ,Stereochemistry ,[CHIM.THER] Chemical Sciences/Medicinal Chemistry ,General Chemical Engineering ,Saccharomyces cerevisiae ,Substrate (chemistry) ,Transporter ,[CHIM.THER]Chemical Sciences/Medicinal Chemistry ,General Chemistry ,biology.organism_classification ,Yeast ,03 medical and health sciences ,chemistry.chemical_compound ,Quinoxaline ,[SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication ,chemistry ,[SDV.SP.PHARMA] Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/Pharmacology ,Potency ,Efflux ,Candida albicans ,030304 developmental biology - Abstract
International audience; Two series of piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives were prepared via a Buchwald–Hartwig cross-coupling reaction and then evaluated for their ability to inhibit the drug efflux activity of CaCdr1p and CaMdr1p transporters of Candida albicans overexpressed in a Saccharomyces cerevisiae strain. In the initial screening of twenty-nine piperazinyl-pyrrolo[1,2-a]quinoxaline derivatives, twenty-three compounds behaved as dual inhibitors of CaCdr1p and CaMdr1p. Only four compounds showed exclusive inhibition of CaCdr1p or CaMdr1p. Further biological investigations were developed and for example, their antifungal potential was evaluated by measuring the growth of control yeast cells (AD1-8u−) and efflux pump-overexpressing cells (AD-CDR1 and AD-MDR1) after exposition to variable concentrations of the tested compounds. The MIC80 values of nineteen compounds ranging from 100 to 901 μM for AD-CDR1 demonstrated that relative resistance index (RI) values were between 8 and 274. In comparison, only seven compounds had RI values superior to 4 in cells overexpressing Mdr1p. These results indicated substrate behavior for nineteen compounds for CaCdr1p and seven compounds for CaMdr1p, as these compounds were transported via MDR transporter overexpressing cells and not by the AD1-8u− cells. Finally, in a combination assay with fluconazole, two compounds (1d and 1f) have shown a synergistic effect (fractional inhibitory concentration index (FICI) values ≤ 0.5) at micromolar concentrations in the AD-MDR1 yeast strain overexpressing CaMdr1p-protein, indicating an excellent potency toward chemosensitization.
- Published
- 2020
- Full Text
- View/download PDF